Meeting
2021 ASCO Annual Meeting
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.
Authors
James Larkin
The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
James Larkin , Helen Gogas , Michele Del Vecchio , Michele Maio , Petr Arenberger , Ana Maria Arance , Jean-Jacques Grob , Vanna Chiarion-Sileni , Karl D. Lewis , Laurent Mortier , Patrick Alexander Ott , Georgina V. Long , Alfonsus Van Den Eertwegh , C. Lance Cowey , Michael Schenker , Marcus O. Butler , Maurice Lobo , Margarita Askelson , Paolo Antonio Ascierto , Jeffrey S. Weber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02388906
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9569)
DOI
10.1200/JCO.2021.39.15_suppl.9569
Abstract #
9569
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.
First Author: Mahrukh M. Syeda
Poster
2023 ASCO Annual Meeting
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.
First Author: Joseph Tintelnot
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Robert R. McWilliams
Poster
2019 ASCO Annual Meeting
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
First Author: Julia Katharina Schwarze